Skip to main content

Experimental corneal allograft rejection

Immunologic Research volume 25, pages 1–26 (2002)Cite this article

Abstract

The major findings regarding corneal allograft rejection in experimental animals are reviewed. The principal anatomic and biological feature of the cornea that dete rmines the immunologic privilege of this tissue is its avascularity. The surgical trauma of transplantation compromises the immunologic privilege, putting corneal allografts at risk for immune rejection. During the past 50 yr, rabbits, rats, and mice have been used extensively in the study of the process of immunologically mediated corneal allograft rejection. It is clear that the inflammation, and neovascularization of the graft that occurs following transplantation predisposes a corneal allograft to the classic cell-mediated immune rejection response. The antigenicity of cornea cells has been studied and has been found to be significantly lower compared to other cells and tissues.

Rejection of acorneal allograft isacell-mediated processdirected against major histocompatibility, complex, antigens involving both CD4+T helper cells and CD8+ cytotoxic cells. The prevention of corneal allograft rejection depends on the development of topically applied compounds that can prevent inflammation and vascularization and inhibit the activation of T lymphocytes. Considerable progress has been made using immunomodulators, including blocking antibodies and soluble coreceptor blocking agents such as CTLA 4-Ig. Combinations of antiangiogenic, agents and immunomodul ators hold gre at promise for preventing corneal allograft rejection in patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Polack FM: Histopathological and histochemical alterations in the early stages of comeal graft rejection. JExpMed 1962; 116: 709–717.

    CAS  Google Scholar 

  2. Kanai A, Polack FM: Ultramicroscopic changes in the comeal graft stromaduring early rejection. Invest Ophthalmol 1971; 10: 415–423.

    PubMed  CAS  Google Scholar 

  3. Polack FM, Kanai A: Electron microscopic studies of graft endothelium in corneal graft rejection. Am J Ophthalmol 1972; 73: 711–717.

    PubMed  CAS  Google Scholar 

  4. Gronemeyer U, Pulhorn G, Muller-Ruchholtz W: Allogeneic corneal grafting in inbred strains of rats. Albrecht v Graefes Arch Klin Exp Ophthalmol 1978; 208: 247–262.

    CAS  Google Scholar 

  5. She S-C, Steahly LP, Moticka EJ: A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse. Ophthalmic Surg 1990; 21: 781–785.

    PubMed  CAS  Google Scholar 

  6. Holland EJ, Chan C-C, Wetzig RP, Palestine AG, Nussenblatt RB: Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model. Cornea 1991; 10: 374–380.

    PubMed  CAS  Google Scholar 

  7. Holland FJ, Olsen TW, Chan C-C, Bergstrom L, Palestine AG, Nussenblatt RB: Kinetics of corneal transplant rejection in the rat penetrating keratoplasty model. Cornea 1994; 13: 317–323.

    PubMed  CAS  Google Scholar 

  8. Larkin DFP, Calder VL, Lightman SL: Identification and characterization of cells infiltrating the graft and aqueous humour in ratcomeal allograft rejection. Clin Exp Immunol 1997; 107: 381–391.

    PubMed  CAS  Google Scholar 

  9. Maumence AE: The influence of donor-recipient sensitization on corneal grafts. Am J Ophthalmol 1951; 34: 142–152.

    Google Scholar 

  10. Chen YF, Gebhardt BM, Reidy JJ, Kaufman HE: Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 1990; 109: 132–137.

    PubMed  CAS  Google Scholar 

  11. Hill JC, Maske R: Ananimal model for corneal graft rejection in high-risk keratoplasty. Transplantation 1988; 46: 26–30.

    PubMed  CAS  Google Scholar 

  12. Medawar PB: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcuta neous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29: 58–69.

    PubMed  CAS  Google Scholar 

  13. Billingham RE, Boswell T: Studies on the problem of comeal homografts. Proc R Soc B 1953: 141: 392–406.

    CAS  Google Scholar 

  14. Polack FM: The effect of ocular inflammation on corneal grafts. Am J Ophthalmol 1965; 60: 259–269.

    PubMed  CAS  Google Scholar 

  15. Inomata H, Smelser GK, Polack FM: Corneal vascularization in experimental uveitis and graft rejection. An electron microscopic study. Invest Ophthalmol 1971; 10: 840–850.

    PubMed  CAS  Google Scholar 

  16. Khodadoust AA, Silverslein AM: Studies on the nature of the privilege enjoyed by corneal allografts. Invest Ophthalmol 1972; 11: 137–148.

    PubMed  CAS  Google Scholar 

  17. Khodadoust AA: Penetrating keratoplasty in the rabbit. Am J Ophthalmol 1968; 66: 899–905.

    PubMed  CAS  Google Scholar 

  18. Khodadoust AA, Silverstein AM: The survival and rejection of epithelium in experimental corneal transplants. Invest Ophthalmol 1969; 8: 169–179.

    PubMed  CAS  Google Scholar 

  19. Salisbury JD, Gebhardt BM: Suppression of corneal allograft rejection by cyclosporin A. Arch Ophthalmol 1981; 99: 1640–1643.

    PubMed  CAS  Google Scholar 

  20. Newton C, Gebhardt BM, Kaufman HE: Topically applied cyclosporine in Azone prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 1988; 29: 208–215.

    PubMed  CAS  Google Scholar 

  21. Guo A, Ohia E, Xu J, Bhattacherjee P, Kulkarni P: Effects of anti-inflammatory and immuno-suppressive drugs on the heterolamellar corneal transplantation in rabbits. Curr Eye Res 1990; 9: 749–757.

    PubMed  CAS  Google Scholar 

  22. Gebhardt BM, Varnell ED, Kaufman HE: Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. J Ocul Pharmacol Thera 1995; 11: 509–517.

    CAS  Google Scholar 

  23. Lang RF, Riekhof FT, Steinmuller D: Interlamellar corneal grafts in rats. Effect of histocompatibility. Arch Ophthalmol 1975; 93: 349–353.

    PubMed  CAS  Google Scholar 

  24. Gebhardt BM: Factors affecting cornealallograft rejection in inbred rats. Transplant Proc XIII: 1981: 1091–1093.

    Google Scholar 

  25. Treseler PA, Treseler CB, Foulks GN, Sanfilippo F: Allospecific cellular and humoral immunity to rat corneal transplants. Transplant Proc 1985; 17: 789–791.

    Google Scholar 

  26. Treseler PA, Sanfilippo F: Humoral immunity to heterotopic comeal allografts in the rat. Transplantation 1985; 39: 193–1201.

    PubMed  CAS  Article  Google Scholar 

  27. Treseler PA, Sanfilippo F: The expression of major histocompatibility complex and leukocyte antigens by cells in the rat cornea. Transplantation 1985; 41: 248–252.

    Article  Google Scholar 

  28. Treseler PA, Sanfilippo F: Relative contribution of major histocompatibility complex antigens to the immunogenicity of corneal allografts. Transplantation 1985; 41: 508–514.

    Article  Google Scholar 

  29. Williams KA, Coster DJ: Penetrating corneal transplantation in the inbred rat: A new model. Invest Ophthalmol Vis, Sci 1985; 26: 23–30.

    CAS  Google Scholar 

  30. Treseler PA, Foulks GN, Sanfilippo F: The relative immunogenicity of corneal epithelium, stroma, and endothelium. Trans-plantation 1986; 41: 229–234.

    CAS  Google Scholar 

  31. Callanan D, Peeler J, Niederkorn JY: Characteristics of rejection of orthotopic corneal allografts in the rat. Transplantation 1988; 45: 437–443.

    PubMed  CAS  Google Scholar 

  32. Katami M, Madden PW, White DJ, Watson PG, Kamada N: The extent of immunological privilege of orthotopic corneal grafts in the inbred rat. Transplantation 1989: 48: 371–376.

    PubMed  CAS  Google Scholar 

  33. Katami M, Lim SML, Kamada N, Davies HFFS, Butcher GW, White DJG, Watson PG, Calne RY: A pure class II MHC disparity does not induce rejection of cornea or heart grafts in the rat. Transplant Proc 1990; 22: 2200–2201.

    PubMed  CAS  Google Scholar 

  34. Ross J, Callanan D, Kunz H, Niederkorn J: Evidence that the fate of class II-disparate comeal grafts is determined by the timing of class 11 expression. Transplantation 1991; 51: 532–536.

    PubMed  CAS  Google Scholar 

  35. Katami M, Graudenz MS, White DJG, Watson PG: The role of antigen-presenting cells in rat corneal graft rejection. Transplant Proc 1991; 23: 93–95.

    PubMed  CAS  Google Scholar 

  36. Ross J, He Y-G, Pidherney M, Mellon J, Niederkom JY: The differential effects of donor versus host Langerhans cells in the rejection of MHC- matched corneal allografts. Transplantation 1991; 52: 857–861.

    PubMed  CAS  Google Scholar 

  37. Torres PF, De Vos AF, Van Der Gaag R, Martins B, Kijlstra A: Cytokine mRNA expression during experimental corneal allograft rejection. Exp Eye Res 1996; 63: 453–461.

    PubMed  CAS  Google Scholar 

  38. King WJ, Comer RM; Hudde T, Larkin DFP, George AJT: Cytokine and chemokine expression kinetics after corneal transplantation. 2000; 70: 1225–1233.

    CAS  Google Scholar 

  39. Ross JR, Sanfilippo FP, Howell DN: Histopathologic features of rejecting orthotopic corneal xenografts. Curr Eye Res 1994; 13: 725–730.

    PubMed  CAS  Google Scholar 

  40. Takano T, Williams KA: Mechanism of corneal endothelial destruction in rejecting rat corneal allografts and xenografts: a role for CD4+ cells. Transplant Proc 1995; 27: 260–261.

    PubMed  CAS  Google Scholar 

  41. Torres PF, Slegers TPAM, Peek R, van Rooijen N, van der Gaag R, Kijlstra A, de Vos AF Changes in cytokine mRNA levels in experimental corneal allografts after local clodronate-liposome treatment. Invest Ophthalmol Vis Sci 1999; 40: 3194–3201.

    PubMed  CAS  Google Scholar 

  42. Peeler JS, Callanan DG, Luckenbach MW, Niederkorn JY: Presentation of the H-Y antigen on Langerhans' cell-negative corneal grafts downregulates the cytotoxic T cell response and converts responder strain mice into phenotypic nonresponders. J Exp Med 1988; 168: 1749–1766.

    PubMed  CAS  Google Scholar 

  43. Joo C-K, Pepose JS, Stuart PM: T-cell mediated responses in a murine model of orthotopic corneal transplantation. Invest Ophthalmol Vis Sci 1995; 36: 1530–1540.

    PubMed  CAS  Google Scholar 

  44. Sonoda Y, Sano Y, Ksander B, Streilein JW: Characterization of cell-mediated immune responses elicited by orthotopic cornea lallografts in mice. Invest Ophthalmol Vis Sci 1995; 36: 427–434.

    PubMed  CAS  Google Scholar 

  45. Holan V, Haskova Z, Filipec M: Transplantation immunity and tolerance in the eye. Rejection and acceptance of orthotopic comeal allografts in mice. Transplantation 1996; 62: 1050–1054.

    PubMed  CAS  Google Scholar 

  46. Yamada J, Kurimoto I, Streilein JW: Role of CD4+ cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci 1999; 40: 2614–2621.

    PubMed  CAS  Google Scholar 

  47. Yamagami S, Tsuru T: Increase in orthotopic murine corneal transplantation rejection rate with anterior synechiae. Invest Ophthalmol Vis Sci 1999; 40: 2422–2426.

    PubMed  CAS  Google Scholar 

  48. Haskova Z, Usiu N, Pepose JS, Ferguson TA, Stuart PM: CD4+T cells are critical forcorneal, but not skin, allograftrejection. Transplantation 2000; 69: 483–487.

    PubMed  CAS  Google Scholar 

  49. Yamagami S, Obata H, Tsuru T, Isobe M: Suppression of comeal allograft rejection after penetrating keratoplasty by antibodies to ICAM-1 and LFA-1 in mice. Transplant Proc 1995; 27: 1899–1900.

    PubMed  CAS  Google Scholar 

  50. Haskova Z, Filipec M, Holan V: The role of major and minor histocom-patibility antigens in orthotopic corneal transplantation in mice. Folia Biologica 1996; 42: 105–111.

    PubMed  CAS  Google Scholar 

  51. Yamagami S, Isobe M, Yamagami H, Hori J, Tsuru T: Mechanism of concordant corneal xenograft rejection in mice. Transplantation 1997; 64: 42–48.

    PubMed  CAS  Google Scholar 

  52. Hori J, Isobe M, Yamagami S, Mizuochi T, Tsuru T: Specific immunosuppression of corneal allograftrejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Exp Eye Res 1997; 65: 89–98.

    PubMed  CAS  Google Scholar 

  53. Yamagami S, Kawashima H, Tsuru T, Yamagami H, Kayagaki N, Yagita H, Okumura K, Gregerson DS: Role of Fas-Fasligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997;64:1107–1111.

    PubMed  CAS  Google Scholar 

  54. Yamagami S, Kawashima H, Endo H, Tsuru T, Shibui H, Isobe M: Cytokine profileso faqueous humor and graft in orthotopic mouse corneal transplantation. Transplantation 1998;66:1504–1510.

    PubMed  CAS  Google Scholar 

  55. Lau CH, Nicholls SM, Easty DL: A murine model of interlamelar comeal transplantation. Br J Ophthalmol 1998;82:294–299.

    PubMed  CAS  Google Scholar 

  56. Kamiya K, Hori J, Obata H, Yamagami S, Tsuru T; Incidence of allograft rejection after corneal transplantation using Optisolpreserved corneas in mice. Transplant Proc 1999;31:2673–2674.

    PubMed  CAS  Google Scholar 

  57. Kamiya K, Hori J, Kagaya F, Usui T, Amano S, Oshika T, Mizouchi T, Tsuru T, Yamagami S: Preservation of donor cornea prevents corneal allograft rejection by inhibiting induction of alloimmunity. Exp Eye Res 2000;70:737–743.

    PubMed  CAS  Google Scholar 

  58. Niederkorn JY, Callanan D, Ross JR: Prevention of the induction of allospecific cytotoxic T lymphocyte and delayed-type hypersensitivity responses by ultraviolet irradiation of corneal allografts. Transplantation 1990;50:281–286.

    PubMed  CAS  Google Scholar 

  59. Niederkorn JY, Mellon J: Anterior chamber-associated immunedeviation promotes corneal allograft survival. Invest Ophthalmol VisSci 1996;37:2700–2707.

    CAS  Google Scholar 

  60. Sano Y, Ksander BR, Streilein JW: Fate of orthotopic corneal allografts in eyes that camot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci 1995; 36:2176–2185.

    PubMed  CAS  Google Scholar 

  61. Sano Y, Ksander BR, Streilein JW: Arune orthotopic corneal transplantation in high-ridkeyes. Rejection is dictated primarily by weak rather than strong alloantigens. Invest Ophthalmol Vis Sci 1997; 38:1130–1138.

    PubMed  CAS  Google Scholar 

  62. Sano Y, Ksander BR, Streilein JW: Langerhans cells, orthotopic corneal allografts, and direct and indirect pathways of T-cell allorecognition. Invest Ophthalmol Vis Sci 2000;41:1422–1431.

    PubMed  CAS  Google Scholar 

  63. Khodadoust AA, Silverstein AM: Transplantation and rejection of individual cell layers of the cornea. Invest Ophthalmol 1969;8 180–195.

    PubMed  CAS  Google Scholar 

  64. Malinowski K, Tsai D, Manski W: The relative capacity of corneal, heart, kidney and skin cells to stimulate allogenic lymphocytes. Immunol Commun 1979;8: 303–311.

    PubMed  CAS  Google Scholar 

  65. Guymer RH, Mandel TE: A comparison of corneal, pancreas, and skin grafts in mice. Transplantation 1994;57:1251–1262.

    PubMed  CAS  Google Scholar 

  66. Gebhardt BM, Seto SK: The immunogenicity of corneal stromal keratocytes. Transplantation 1988; 46:444–448.

    PubMed  CAS  Google Scholar 

  67. Gebhardt BM: The effect of tissue dose and site of grafting on immunity to corneal allografts. Invest Ophthalmol Vis Sci 1988;29: 1663–1670.

    PubMed  CAS  Google Scholar 

  68. Nicholls SM, Bradley BB, Easty DL: Effect of mismatches for major histocompatibility complex and minor antigens oncorneal graft rejection. Invest Ophthalmol Vis Sci 1991;32:2729–2734.

    PubMed  CAS  Google Scholar 

  69. Sonoda Y, Streilein JW: Orthotopic corneal transplantation in mice—evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992;54:694–704.

    PubMed  CAS  Google Scholar 

  70. Nicholls SM, Bradley BA, Easty DL: Apparent resistance to immunosuppression of MHC-matched corneal transplants. Transplantation 1995;59:325–329.

    PubMed  CAS  Google Scholar 

  71. Bradley BA, Vail A, Gore SM, Rogers CA, Armitage WJ, Nicholls S, Easty DL: Negative effect of HLA-DR matching on corneal transplant rejection. Transplant Proc 1995;27:1392–1394.

    PubMed  CAS  Google Scholar 

  72. Gore SM, Vail A, Bradley BA, Rogers CA, Easty DL, Annitage WJ: HLA-DR matching in comeal transplantation. Transplantation 1995;60:1033–1039.

    PubMed  CAS  Google Scholar 

  73. Forrester D. Non-HLA antigens and HLA-DR matching in comeal transplantation. Br J Ophthalmol 1996;80:780–783.

    Google Scholar 

  74. Graff RJ: Minor histocompati bility genes and their antigens. In: Origins of Inbred Mice, Morse HC III, editor. Academic Press, 1978, pp. 371–389.

  75. Brown J, Soderstrom CW, Winkelmann RK: Langerhans' cells in guinea pig cornea: response to chemical injury. Invest Ophthalmol 1968;7:668–671.

    PubMed  CAS  Google Scholar 

  76. Streilein JW, Toews GB, Bergstresser PR: Corneal allografts fail to express Ia antigens. Nature 1979;282:326–327.

    PubMed  CAS  Google Scholar 

  77. Bergstresser PR, Fletcher CR, Streilein JW: Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J Invest Dennatol 1980;74:77–80.

    CAS  Google Scholar 

  78. Streilein JW, Toews GB, Bergstresser PR: Langerhans cells: functional aspects revealed by in vivo grafting studies. J Invest Dermatol 1980; 75:17–21.

    PubMed  CAS  Google Scholar 

  79. Gillette TE, Chandler JW: Immunofluorescence and histochemistry of corneal epithelial flat mounts: use of EDTA. Curr Eye Res 1981;1: 249–253.

    PubMed  CAS  Google Scholar 

  80. Gillette TE, Chandler JW, Greiner JV: Langerhans cells of the ocular surface. Ophthalmology 1982;89:700–711.

    PubMed  CAS  Google Scholar 

  81. Hazlett LD, Grevengood C, Berk RS: Change withage in limbalconjunctioval Langerhans cells. Curr Eye Res 1982;2:423–425.

    PubMed  Google Scholar 

  82. Braude LS, Chandler JW: Corneal allograft rejection. The role of the major histocompatibility complex. Surv Ophthalmol 1983;27: 290–305.

    PubMed  CAS  Google Scholar 

  83. Rodrigues MM, Rowden G, Hackett J, Bakos I: Langerhans cells in the normal conjunctiva and peripheral cornea of selected species. Invest Ophthalmol Vis Sci 1981; 21:759–765.

    PubMed  CAS  Google Scholar 

  84. Choudhury A, Pakalnis VA, Bowers WE: Function and cellsurface phenotype of dendritic cells from rat cornea. Invest Ophthalmol Vis Sci 1995;36:2602–2613.

    PubMed  CAS  Google Scholar 

  85. Rubsamen PE, McCulley, J, Bergstresser PR, Streilein JW: On the Ia immunogenicity of mouse corneal allografts infitrated with Langerhans cells. Invest Ophthalmol Vis Sci 1984;25:513–518.

    PubMed  CAS  Google Scholar 

  86. Ray-Keil L, Chandler LW: Rejection of murine heterotopic corneal transplants. Transplantation 1985; 39:473–477.

    PubMed  CAS  Article  Google Scholar 

  87. Peeler JS, Niederkorn JY: Effect of Langerhans' cells on cytotoxic T lymphocyte responses to major and minor alloantigens expressed on heterotopic corneal allografts. Transplant Proc 1987; 19 (part 1): 316–319.

    PubMed  CAS  Google Scholar 

  88. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189–1192.

    PubMed  CAS  Google Scholar 

  89. Hori J, Joyce N, Streilein JW: Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest Ophthalmol Vis Sci 2000;41: 443–451.

    PubMed  CAS  Google Scholar 

  90. Hori J, Joyce NC, Streilein JW: Immune privilege and immunogenicity reside among different layerson the mouse comea. Invest Ophthalmol Vis Sci 2000; 41: 3032–3042.

    PubMed  CAS  Google Scholar 

  91. Wackenheim-Urlacher A, Kantelip B, Falkenrodt A, Piqot X, Tongio M-M, Montard M, Delbose B: T-cell repertoire of normal, rejected, and pathological comeas: phenotype and function. Cornea. 1995;14:450–456.

    PubMed  CAS  Google Scholar 

  92. Kang S-M, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997;3: 738–743.

    PubMed  CAS  Google Scholar 

  93. Kaplan HJ, Streilein JW: Immune response to immunization via the anterior chamber of the eye. II. An analysisof Fl lymphocyte-induced immune deviation. J Immunol 1978;120:689–693.

    PubMed  CAS  Google Scholar 

  94. Niederkorn J, Streilein JW, Shadduck JA: Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci 1981;20: 355–363.

    PubMed  CAS  Google Scholar 

  95. Niederkorn JY, Streilein JW: Analysis of antibody production induced by allogeneic tumor cells incculated in to the anterior chamber of the eye. Transplantation 1982;33:573–577.

    PubMed  CAS  Google Scholar 

  96. Whittum JA, Niederkorn JY, McCulley JP, Streilein JW: Intracameralinoculation of herpessimplex virus type I induces anterior chamber associated immune deviation. Curr Eye Res 1983;2: 691–697.

    CAS  Google Scholar 

  97. Niederkorn JY, Streilein JW: Alloantigens placed into the anterior chamber of theey einduce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. J Immunol 1983; 131:2670–2674.

    PubMed  CAS  Google Scholar 

  98. Mizuno K, Clark AF, Streilein JW: Induction of anterior chamber associated immune deviation in rats receiving intracameral injections of retinal S antigen. Curr Eye Res 1988;7:627–632.

    PubMed  CAS  Google Scholar 

  99. Benson JL, Niederkorn JY: Immune privilege in the anterior chamber of the eye: alloantigens and tumour-specific antigens presented into the anterior chamber simultaneously induce suppression and activation of delayed hypersensitivity to the respective antigens. Immunology 1992;77:189–195.

    PubMed  CAS  Google Scholar 

  100. Whittum JA, Niederkorn JY, McCulley JP, Streilein JW: Role of suppressor T cells in herpes simplex virus-induced immune deviation. J Virol 1984;51:556–558.

    PubMed  CAS  Google Scholar 

  101. Niederkorn JY, Waltenbaugh C, Streilein JW: Abrogation of anterior-chamber-induced suppression of delayed-typehypersensitivity responses by monoclonal anti-I-J antibodies. Transplantation 1984;37:623–625.

    PubMed  CAS  Article  Google Scholar 

  102. Williamson JSP, Streilein JW: Impaired induction of delayed hypersensitivity followinganterior chamber inoculation of alloantigens. Regional Immunol 1988;1: 15–23.

    CAS  Google Scholar 

  103. Wilbanks GA, Streilein JW: Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology 1990;71:383–389.

    PubMed  CAS  Google Scholar 

  104. Williamson JSP, Bradley D, Streilein JW: Immunoregulatory properties of bonemarrow-derived cells in the iris and ciliary body. Immunology 1989;67:1–8.

    Google Scholar 

  105. Okamoto S, Hara Y, Streilein JW: Induction of anterior chamberassociated immune deviation with lymphoreticular allogeneic cells. Transplantation 1995;59:377–381.

    PubMed  CAS  Google Scholar 

  106. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkom JY: Cutting edge: role of macrophage migration in hibitory factor in inhibiting NK cellactivity and preserving immune privilege. J Immunol 1998;160:5693–5696.

    PubMed  CAS  Google Scholar 

  107. Niederkorn JY, Mayhew E: Role of splenic B cells in the immune privilege of the anterior chamber of the eye. Eur J Immunol 1995; 25:2783–2787.

    PubMed  CAS  Google Scholar 

  108. Williamson JSP, Streilein JW: Induction of delayed hypersensitivity to alloantigens coinjected with Langerhans cells into the anterior chamber of the eye. Transplantation 1989;47:519–524.

    PubMed  CAS  Google Scholar 

  109. Ksander BR, Bando Y, Acevedo J, Streilein JW: Infiltration and accumulation of precursor cytotoxic T-cells increased with time inprogressively growing ocular tumors. Cancer Res 1991;51:3153–3158.

    PubMed  CAS  Google Scholar 

  110. Benson JL, Niederkom JY: In situ suppression of delayed-typehypersensitivity: an other mechanism for sustaining the immune privilege of the anteriorchamber. Immunology 1991;74:153–159.

    PubMed  CAS  Google Scholar 

  111. Kosiewicz MM, Streilein JW: Intraocular injection of classII-restricted peptide inducesan unexpected population of CD8 regulatory cells. J Immunol 1996;157:1905–1912.

    PubMed  CAS  Google Scholar 

  112. Kezuka T, Streilein JW: In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamberassociated immunie deviation. Invest Ophthalmol Vis Sci 2000; 41:1803–1811.

    PubMed  CAS  Google Scholar 

  113. Bando Y, Ksander BR, Streilein JW, Characterization of specific T helper cell activity in ice bearing alloantigenic tumors in the anterior chamber of the eye. Eur J Immunol 1991; 21:1923–1931.

    PubMed  CAS  Google Scholar 

  114. Li X-Y, D'Orazio T, Niederkorn JY: Role of Th1 and Th2 in anterior chamber-associated immune deviation. Immunology 1996;89: 34–40.

    PubMed  CAS  Google Scholar 

  115. Takahashi M, Ishimaru N, Yanagi K, Saegusa K, Haneji N, Shiota H, Hayashi Y: Requirement for splenic CD4+ T cells in the immune privilege of the anterior chamber of the eye. Clin Exp Immunol 1999;116:231–237.

    PubMed  CAS  Google Scholar 

  116. Cousins SW, McCabe MM, Danielpour D, Streilein JW: Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991; 32:2201–2211.

    PubMed  CAS  Google Scholar 

  117. Wilbanks GA, Streilein JW: Fluids of immune privileged sites endow macrophages with the capacity to induceantigen-specific immune deviation via a mechanism involving transforming growth factor-β. Eur J Immunol 1992;22: 1031–1036.

    PubMed  CAS  Google Scholar 

  118. Taylor AW, Alarad P, Ye DG, Streilein JW: Aqueous humor induces transforming growth factor-β (TGF-β)-producing regulatory T-cells. Curr Eye Res 1997; 16:900–908.

    PubMed  CAS  Google Scholar 

  119. Takeuchi M, Alard P, Streilein JW: TGF-β promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol 1998;160:1589–1597.

    PubMed  CAS  Google Scholar 

  120. Kosiewicz MM, Alard P, Streilein JW: Alterations in cytokine production following intraocular injection of soluble protein antigen: impairment in IFN-γ and induction of TGF-β and IL-4 production. J Immunol 1998;161: 5382–5390.

    PubMed  CAS  Google Scholar 

  121. Ohta K, Wiggert B, Yamagami S, Taylor AW, Streilein JW: Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol 2000;164: 1185–1192.

    PubMed  CAS  Google Scholar 

  122. Kezuka T, Streilein JW: Analysis of in vivo regulatory properties of T cells activated in vitro by TGFβ2-treated antigen presenting cells. Invest Ophthalmol Vis Sci 2000; 41:1410–1421.

    PubMed  CAS  Google Scholar 

  123. Ohta K, Yamagami S, Taylor AW, Streilein JW: IL-6 antagonizes TGF-β and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2000;41:2591–2599.

    PubMed  CAS  Google Scholar 

  124. Benson JL, Niederkorn JY: Interleukin-1 abrogates anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 1990; 31:2123–2128.

    PubMed  CAS  Google Scholar 

  125. Dara MR, Dai R, Zhu S, Yamada J, Streilein JW: Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege. Invest Ophthalmol Vis Sci 1998; 39:70–77.

    Google Scholar 

  126. Niederkorn JY: Exogenous recombinant interleukin-2 abrogates anterior-chamber-associated immune deviation. Transplantation 1987;43:523–528.

    PubMed  CAS  Google Scholar 

  127. D'Orazio TJ, Niederkorn JY: A novel role for TGF-β and IL-10 in the induction of immuneprivilege. J Immunol 1998;160:2089–2098.

    PubMed  Google Scholar 

  128. Streilein JW, Cousins S, Bradley D: Effect of intraocular gamma-interferon on immunoregulatory properties of iris and ciliary body cells. Invest Ophthalmol Vis Sci 1992;33:2304–2315.

    PubMed  CAS  Google Scholar 

  129. Geiger K, Sarvetnick N: Local production of IFN-γ abrogates the intraocular immune privilege in transgenic mice and prevents the induction of AC AID. J Immunol 1994;153:5239–5246.

    PubMed  CAS  Google Scholar 

  130. Ferguson TA, Herndon JM, Dube P: The immune response and the eye: a role for TNFα in anlerior chamber-associated immunedeviation. Invest Ophthalmol Vis Sci 1994;35:2643–2651.

    PubMed  CAS  Google Scholar 

  131. Ferguson TA, Fletcher S, Herndon J, Griffith TS: Neuropeptides modulate immune deviation induced via theanterior chamber of the eye. J Immunol 1995;155:1746–1756.

    PubMed  CAS  Google Scholar 

  132. Knisely TL, Hosoi J, Nazareno R, Granstein RD: The presence of biologically significant concentrations of glucocorticoids but little or no cortisol binding globulin within aqueous humor: relevance to immune privilege in the anterior chamber of the eye. Invest Ophthalmol Vis Sci 1994;35: 3711–3723.

    PubMed  CAS  Google Scholar 

  133. Apte RS, Niederkorn JY: Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol 1996;156: 2667–2673.

    PubMed  CAS  Google Scholar 

  134. Ferguson TA, Hayashi JD, Kaplan HJ: The immune response and the eye. III. Anterior chamber-associated immune deviation can beadoptively transferred by serum. J Immunol 1989;143:821–826.

    PubMed  CAS  Google Scholar 

  135. Wilbanks GA, Streilein JW: Studies on the induction of anterior chamber-associated immunedeviation (ACAID). I. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol 1991;146:2610–2617.

    PubMed  CAS  Google Scholar 

  136. Hadjikouti CA, Wang Y, O'Rourke J, Cone RE: Intracameral injection of antigen potentiates the production of antigen-specific T cell proteins in serum after the induction of delayed-type hypersensitivity. Invest Ophthalmol Vis Sci 1995; 36:1470–1476.

    PubMed  CAS  Google Scholar 

  137. Streilein JW, Okamoto S, Hara Y, Kosiewicz M, Ksander B: Blood-borne signals that induce anterior chamber-associated immunedeviation after intracameral injection of antigen. Invest Ophthalmol Vis Sci 1997;38:2245–2254.

    PubMed  CAS  Google Scholar 

  138. Yamada J, Streilein JW: Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber. Invest Ophthalmol Vis Sci 1997;38:2833–2843.

    PubMed  CAS  Google Scholar 

  139. Yamada J, Yoshida M, Taylor AW, Streilein JW: Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in “high risk” eyes. J Immunol 1999;162:5247–5255.

    PubMed  CAS  Google Scholar 

  140. Tanaka K, Yamada J, Joyce N, Streilein JW: Immunobiology of xenogenic cornea grafts in mouse eyes. Transplantation 2000;69: 610–616.

    PubMed  CAS  Google Scholar 

  141. Ferguson TA, Griffith TS: A vision of cell death: insights into immune privilege. Immunol Rev 1997; 156:167–184.

    PubMed  CAS  Google Scholar 

  142. Streilein JW: Anterior chamber associated immune deviation: the privilege of immunity in the eye. Surv Ophthalmol 1990;35:67–73.

    PubMed  CAS  Google Scholar 

  143. Streilein JW, Wilbanks GA, Cousins SW: Immunoregulatory mechanisms of the eye. J Neuroimmunol 1992;39:185–200.

    PubMed  CAS  Google Scholar 

  144. Streilein JW: Ocularimmune privilege and the Faustian dilemma. The Proctor Lecture. Invest Ophthalmol Vis Sci 1996;37:1940–1950.

    PubMed  CAS  Google Scholar 

  145. Streilein JW: Immunoregulatory mechanisms of the eye. Prog Retin Eye Res 1999;18: 357–370.

    PubMed  CAS  Google Scholar 

  146. Niederkorn JY: The immune privilege of comeal allografts. Transplantation 1999;67:1503–1508.

    PubMed  CAS  Google Scholar 

  147. Streilein JW: Immunologic privilege of the eye. Springer Semin Immunopathol 1999;21:95–111.

    PubMed  CAS  Google Scholar 

  148. Sonoda Y, Streilein JW: Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol 1993;150: 1727–1734.

    PubMed  CAS  Google Scholar 

  149. Hodkin MJ: Complications of penetrating keratoplasty. In: The Cornea, Kaufman HE, Barron BA, McDonald MB, editors. Butterworth-Heinemann, Boston, 1998, pp 847–878.

    Google Scholar 

  150. Jones BR: Summing up. Present knowledge and problems of comeal graft failure. In: Corneal Graft Failure, Ciba Foundation Syposium, Elsevier, Amsterdam, 1973, pp 349–354.

    Google Scholar 

  151. Liu L, Sun YK, Xi YP, Maffei A, Reed E, Harris P, Suciu-Foca N: Contribution of directand indirect recognition pathways to T cell alloreactivity. J Exp Med 1993; 177:1643–1650.

    PubMed  CAS  Google Scholar 

  152. Shoskes DA, Wood KJ: Indirect presentation of MHC antigens in transplantation. Immunol Today 1994;15:32–38.

    PubMed  CAS  Google Scholar 

  153. Van Der Veen G, Broersma L, Dijkstra CK, Van Rooijen N, Van Rij G, Van Der Gaag R: Prevention of comeal allo graft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci 1994; 35:3505–3515.

    PubMed  Google Scholar 

  154. Van der Veen G, Broersma L, Van Rooijen N, Van Rij G, Van der Gaag R: Cytotoxic T lymphocytes and antibodies after orthotropic penetrating keratoplasty in rats treated with dichloromethylene diphosphonate encapsulated liposomes. Curr Eye Res 1998;17: 1018–1026.

    PubMed  Google Scholar 

  155. Slegers TPAM, van Rooijen N, van Rij G, van der Gaag R: Delayed graft rejection in pre-vascularized corneas after subconjunctival injection of clodronate liposomes. Curr Eye Res 2000;20: 322–324.

    PubMed  CAS  Google Scholar 

  156. Slegers TPAM, Torres PF, Broersma L, van Rooijen N, van Rij G, van der Gaag R: Effect of macrophage depletion on immune effector mechanisms during corneal allograft rejection in rats. Invest Ophthalmol Vis Sci 2000; 41:2239–2247.

    PubMed  CAS  Google Scholar 

  157. Duguid IGM, Koulmanda M, Mandel TE: Prolongation of heterotopic human corneal graft survival in mice treated with an anti-CD4 monoclonal antibody. Transplant Proc 1990;22: 2107–2108.

    PubMed  CAS  Google Scholar 

  158. He YG, Ross J, Niederkorn JY: Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991;32: 2723–2728.

    PubMed  CAS  Google Scholar 

  159. Ayliffe W, Alam Y, Bell EB, McLeod D, Hutchinson IV: Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol 1992;76:602–606.

    PubMed  CAS  Google Scholar 

  160. Williams KA, Coster DJ: Monoclonal antibodies in corneal transplantation. Br J Ophthalmol 1992;76:577.

    PubMed  CAS  Google Scholar 

  161. Takano T, Williams KA: Mechanism of corneal endothelial destruction in rejecting rat corneal allografts and xenografts: a role of CD4+ cells. Transplant Proc 1995; 27:260–261.

    PubMed  CAS  Google Scholar 

  162. Pleyer U, Milani JK, Dukes A, Chou J, Lutz S, Ruckert D, Thiel H-J, Mondino BJ: Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a ratmodel. Invest Ophthalmol Vis Sci 1996;35:52–61.

    Google Scholar 

  163. Tanaka K, Yamada J, Streilein JW: Xenoreactive CD4+ T cells and acute rejection of orthotopic guinea pigcomeans in mice. Invest Ophthalmol Vis Sci 2000;41: 1827–1832.

    PubMed  CAS  Google Scholar 

  164. Belin MW, Bouchard CS, Frantz S, Chmielinska J: Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989;96: 1144–1150.

    PubMed  CAS  Google Scholar 

  165. Hill JC: The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989;107:506–510.

    PubMed  CAS  Google Scholar 

  166. Waldock A, Cook SD: Corneal transplantation: how successful are we?. Br J Ophthalmol 2000;84: 813–815.

    PubMed  CAS  Google Scholar 

  167. Dana MR, Qian Y, Hamrah P: Twenty-five-year panorama of corneal immunology. Emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 2000;19:625–643.

    PubMed  CAS  Google Scholar 

  168. Hill JC, Maske R, Watson P: Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology 1991;98: 329–333.

    PubMed  CAS  Google Scholar 

  169. Williams KA, Rodner D, Esterman A, Muehlberg SM, Coster DJ: Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology 1992;99:403–414.

    PubMed  CAS  Google Scholar 

  170. Bouchard CS, Cavanagh HD: The high-risk keratoplasty, patient—quo vadis?. Cornea 1994;13:1–3.

    PubMed  CAS  Google Scholar 

  171. Reinhard T, Sundmacher R, Heering P: Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 1996; 234:S115-S121.

    PubMed  CAS  Google Scholar 

  172. Kaliss N: Immunological enhancement. Int Rev Exp Pathol 1969;8: 241–276.

    PubMed  CAS  Google Scholar 

  173. Carpenter CB, d'Apice AJF, Abbas AK: The role of antibodies in the rejection and enhancement of organallografts. Adv Immunol 22: 1–65, 1976.

    PubMed  CAS  Article  Google Scholar 

  174. Batchelor JR: The riddle of kidney graft enhancement. Transplantation 1978;26:139–141.

    PubMed  CAS  Article  Google Scholar 

  175. Chandler JW, Gebhardt BM, Kaufman HE: Immunologic protection of rabbit corneal allografts: preparation and in vitro testing of heterologous “blocking” antibody. Invest Ophthalmol 1973;12: 646–653.

    PubMed  CAS  Google Scholar 

  176. Chandler JW, Gebhardt BM, Sugar J, Kaufman HE: Immunologic protection of rabbit corneal allografts. Transplantation 1974;17:146–148.

    PubMed  CAS  Article  Google Scholar 

  177. Binder PS, Gebhardt BM, Chandler JW, Kaufman HE: Immunologic protection of rat corneal antibodies with heterologous blocking antibody. Am J Ophthalmol 1975;79:949–954.

    PubMed  CAS  Google Scholar 

  178. Gebhardt BM, Varnell ED, Kaufman HE: Prolonged survival of corneal allografts incubated in alloantibody fragments. Transplantation 1999;67:594–599.

    PubMed  CAS  Google Scholar 

  179. Gebhardt BM, Hodkin M, Vamell ED, Kaufman HE: Protection of corneal allografts by CTLA4-Ig. Cornea 1999;18:314–320.

    PubMed  CAS  Google Scholar 

  180. Greenfield EA, Nguyen KA, Kuchroo VK: CD28/B7 costimulation: a review. Crit Rev Immunol 1998;18:389–418.

    PubMed  CAS  Google Scholar 

  181. McCoy KD, Le Gros G: The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999;77:1–10.

    PubMed  CAS  Google Scholar 

  182. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174:561–569.

    PubMed  CAS  Google Scholar 

  183. Lenschow DJ, Zeng Y, Thistlewaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogenic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257: 789–792.

    PubMed  CAS  Google Scholar 

  184. Bolling SF, Lin H, Wei R-Q, Linsley P, Turka LA: The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. J Surg Res 1994;57: 60–64.

    PubMed  CAS  Google Scholar 

  185. Lin H, Wei R-Q, Gordon D, Linsley, P, Turka LA, Bolling SF: Review of CTLA41g use for allograft immunosuppression. Transplant Proc 1994;26:3200–3201.

    PubMed  CAS  Google Scholar 

  186. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB: Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995;155:1165–1174.

    PubMed  CAS  Google Scholar 

  187. Yin D, Fathman CG: Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA41g. J Immunol 1995;155:1655–1659.

    PubMed  CAS  Google Scholar 

  188. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94: 8789–8794.

    PubMed  CAS  Google Scholar 

  189. Onodera K, Chandraker A, Schaub M, Stadlbauer THW, Korom S, Peach R, Linsley PS, Sayegh MH, Kupiec-Weglinski JW: CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients. J Immunol 1997;159: 1711–1717.

    PubMed  CAS  Google Scholar 

  190. Rey-Chaudhury P, Nickerson PW, Manfro RC, Zheng XX, Steiger J, Li YS, Strom TB: CTLA4Ig attenuates accelerated rejection (presensitization) in the mouse islet allograft model. Transplantation 1997;64:172–175.

    Google Scholar 

  191. Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thistlethwait JR Jr, Bluestone JA: Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997;159:5187–5191.

    PubMed  CAS  Google Scholar 

  192. Judge TA, Wu Z, Zheng X-G, Sharpe AH, Sayegh MH, Turka LA: The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999; 162:1947–1951.

    PubMed  CAS  Google Scholar 

  193. Herbort CP, de Smet MD, Roberge FG, Nussenblatt RB, FitzGerald D, Lorberboum-Galski H, Pastan I: Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. Transplantation 1991;52: 470–474.

    PubMed  CAS  Google Scholar 

  194. He Y-G, Mellon J, Niederkorn JY: The effect of oral immunization on corneal allograft survival. Transplantation 1996;61: 920–926.

    PubMed  CAS  Google Scholar 

  195. Ma D, Mellon J, Niederkorn JY: Oral immunisation as a strategy for enhancing corneal allograft survival. Br J Ophthalmol 1997;81: 778–784.

    PubMed  CAS  Google Scholar 

  196. Ma D, Mellon J, Niederkorn JY: Conditions affecting corneal allograft survival by oral immunization. Invest Ophthalmol Vis Sci 1998;39:1835–1846.

    PubMed  CAS  Google Scholar 

  197. Ma D, Li X-Y, Mellon J, Niederkorn JY: Immunologic phenotype of hosts orally immunized with corneal alloantigens. Invest Ophthalmol Vis Sci 1998;39: 744–753.

    PubMed  CAS  Google Scholar 

  198. Chandler JW, Ray-Keil L, Gillette TE: Experimental corneal allograft rejection: description of murine model and a new hypothesis of immunopathogenesis. Curr Eye Res 1983;2:387–397.

    CAS  Google Scholar 

  199. Ray-Keil L, Chandler JW: Reduction in the incidence of rejection of heterotopic murine corneal transplants by pretreatment with ultraviolet radiation. Transplantation 1986;42:403–406.

    PubMed  CAS  Google Scholar 

  200. Guymer RH, Mandel TE: UV-B irradiation of donor skin and cornea prior to allotransplantation in mice. Transplant Proc 1989;21: 3771–3772.

    PubMed  CAS  Google Scholar 

  201. Dana MR, Olkowski ST, Ahmandian H, Stark WJ, Young EM: Lowdose ultraviolet-B irradiation of donor corneal endothelial and graft survival. Invest Ophthalmol Vis Sci 1990;31:2261–2268.

    PubMed  CAS  Google Scholar 

  202. Katami M, White DJG, Watson PG: Site-specific immunosuppression for corneal graft survival in the rat. Transplant Proc 1992; 24:1406–1408.

    PubMed  CAS  Google Scholar 

  203. Hill JC, Sarvan J, Maske R, Els WJ: Evidence that UV-B irradiation decreases corneal Langerhans cells and improves corneal graft survival in the rabbit. Transplantation 1994;57:1281–1283.

    PubMed  CAS  Article  Google Scholar 

  204. He Y-G, Niederkorn JY: Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea 1996;15: 82–89.

    PubMed  CAS  Google Scholar 

  205. Yatoh S, Kawakami Y, Imai M, Kozawa T, Segawa T, Suzuki H, Yamashita K, Okuda Y: Effect of a topically applied neutralizingantibody against vascular endothelial growth factor on corneal allograft rejection of rat. Transplantation 1998;66:1519–1524.

    PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Bryan M. Gebhardt Ph.D.

    Present address: Lions Eye Research Laboratories, LSU Eye Center, LSU Health Sciences Center, 2020 Grmvier Street, Sute B, 70112-2234, Nea Orleans, LA

  2. Weiyun Shi

    Present address: Shandong Eye Institute and Hospital, 5 Yanerdao Road, 266071 P.R., Quingdao, China

Affiliations

  1. Lions Eye Research Laboratories, LSU Eye Center, LSU Health Sciences Center, 2020 Grmvier Street, Sute B, 70112-2234, Nea Orleans, LA

    Weiyun Shi

Authors
  1. Bryan M. Gebhardt Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weiyun Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gebhardt, B.M., Shi, W. Experimental corneal allograft rejection. Immunol Res 25, 1–26 (2002). https://doi.org/10.1385/IR:25:1:01

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/IR:25:1:01

Key Words

  • Cornea
  • Allograft
  • Rejection
  • Vascularization
  • Cell-mediated immunity
  • Immunologic privilege
  • Rabbit
  • Mouse
  • Rat
  • Immunosuppression